FDA 483 - PLZ Corp - December 22, 2022

An FDA inspection of 220 Laboratories, LLC in Riverside, CA, revealed significant deficiencies in their quality control and manufacturing practices. The firm failed to thoroughly investigate numerous customer complaints and out-of-specification environmental monitoring results, including mold contamination. Additionally, the quality unit did not ensure proper batch record calculations, and employees lacked up-to-date GMP training.